Format

Send to

Choose Destination
See comment in PubMed Commons below
Semin Radiat Oncol. 2014 Apr;24(2):94-104. doi: 10.1016/j.semradonc.2014.01.001.

Defining the role of adjuvant therapy: cholangiocarcinoma and gall bladder cancer.

Author information

1
Department of Radiation Oncology, The Ohio State University, Columbus, OH.
2
Department of Radiation Medicine, Oregon Health and Science University, Portland, OR.
3
Department of Radiation Medicine, Oregon Health and Science University, Portland, OR. Electronic address: thomasch@ohsu.edu.

Abstract

Biliary tract cancers are a rare subgroup of malignancies that include gall bladder carcinoma and cholangiocarcinoma. They generally carry a poor prognosis based on the advanced nature of disease at presentation and overall treatment refractoriness. Surgical resection remains the optimal treatment for long-term survival, with consideration of neoadjuvant or adjuvant therapies. In this review, we summarize the role of adjuvant treatments including radiation therapy, chemotherapy, and concurrent chemoradiation with the existing clinical evidence for each treatment decision. Given the rarity of these tumors, the evidence provided is based largely on retrospective studies, Surveillance, Epidemiological, and End Results (SEER) database inquiries, single- or multi-institutional prospective studies, and a meta-analysis of adjuvant therapy studies. Currently, there is no adjuvant therapy that has been agreed upon as a standard of care. Results from prospective, multi-institutional phase II and III trials are awaited, along with advances in molecular targeted therapies and radiation techniques, which will better define treatment standards and improve outcomes in this group of diseases.

PMID:
24635866
DOI:
10.1016/j.semradonc.2014.01.001
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center